Centrosomal protein 55 (CEP55) is a microtubule-bundling protein that participants in cell mitosis. It is overexpressed in several solid tumours and promotes the growth and invasion of cancer cells. However, the role of CEP55 in pancreatic cancer (PANC) remains unclear. Herein, upregulated expression of CEP55 (associated with poor prognosis) was detected in PANC using quantitative real-time reverse transcription PCR, western blotting, and immunohistochemistry. Cell migration, colony formation, wound-healing, and Transwell matrix penetration assays, revealed that upregulation of CEP55 promoted PANC cells proliferation, migration, and invasion in vitro, whereas knockdown of CEP55 attenuated it. In an in vivo murine model, CEP55 overexpression accelerated PANC cells tumourigenicity, together with upregulation of the protein levels of invasion-related proteins matrix metalloproteinase (MMP)2, MMP9, and proliferation-related protein Cyclin D1. Downregulation of CEP55 had the reverse effect. Moreover, the nuclear factor κB (NF-κB)/IκBα signalling pathway, which was activated in CEP55-transduced PANC cells and inhibited in CEP55-silenced PANC cells, contributed to CEP55-mediated PANC cell aggressiveness. This study provided new insights into the oncogenic roles of CEP55 and the mechanism by which the NF-κB pathway is hyperactivated in patients with PANC, indicating that CEP55 is a valuable prognostic factor and a potential therapeutic target in PANC.
Pancreatic cancer (PANC) is one of the most aggressive human malignancies, with a median survival of 3–6 months and an overall 5-year survival rate of less than 5%1, 2. The poor prognosis is mainly attributed to the high aggressiveness of PANC and the absence of symptoms in the early stage, resulting in locally advanced or metastatic disease at diagnosis3, 4. Conventional chemotherapy remains the major option for most PANC patients and surgical resection provides the only chance to cure patients with PANC; However, it provides limited overall survival benefit5, 6. Therefore, there is an urgent need to develop new diagnostic biomarkers and novel therapeutic strategies to improve the clinical outcome of PANC7.
Nuclear factor κB (NF-κB) has been identified as a key player in the regulation of caner development8. Recent research has shown that constitutive activation of the NF-κB pathway is tightly associated with tumourigenesis, migration, and invasion in human carcinomas, including PANC9, 10. Up to 70% of pancreatic ductal adenocarcinoma shows a constitutive activation of the NF-κB pathway, which contributes to epithelial-mesenchymal transition, migration, and invasion9, 11, 12. NF-κB Pathway activation induced by insulin-like growth factor-binding protein (IGFBP2) drives epithelial-mesenchymal transition and invasion in pancreatic ductal adenocarcinoma13. Stimulation of the NF-κB pathway mediated by p-21 activated kinase 4 (PAK4) promotes proliferation and survival of pancreatic cancer cells14. Thus, blocking this pathway might prove clinically effective in inhibiting tumour development and offer valuable therapeutic targets for PANC.
Centrosomal protein 55 (CEP55), one of the centrosomal family proteins, is identified as a microtubule-bundling protein that participants in critical cell functions, such as cell growth, transformation, and cytokinesis15, 16. Increasing evidence shows that CEP55 is overexpressed in premalignant lesions of the colon and in several solid tumours, including human colon cancer, hepatocellular carcinoma, and bladder cancer17,18,19. Importantly, overexpression of CEP55 promoted cell cycle transition in human gastric cancer15; whereas knockdown of CEP55 inhibited cell growth in breast cancer20 and gastric cancer15, decreased cellular motility and invasion in ovarian cancer cells21, and induced cell apoptosis in glioma22. These results suggested that CEP55 might serve an oncogenic role and could be a potential target for tumour treatment. However, the clinical significance and biological role of CEP55 in PANC remain largely unclear.
In the present study, we provided evidence that CEP55 overexpression increased the activity of NF-κB and promotes PANC cell proliferation, migration/invasion, and tumourigenicity in vitro and in vivo, which conferred poor prognosis in patients with PANC. In contrast, blocking the NF-κB pathway suppressed the CEP55-induced aggressiveness of PANC cells. The results provided new insight into the mechanisms underlying the hyperactivation of NF-κB pathway in PANC and suggest that CEP55 might be a valuable prognostic factor and potential target in PANC therapy.
Materials and Methods
Normal pancreas cell line hTERT-HPNE (Human Pancreatic Nestin Expressing cells) and eight different human PANC cell lines (Panc 03.27, Capan-1, Capan-2, SW1990, HPAF-II, Panc 10.05, BxPC-3, and CFPAC-1) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% foetal bovine serum (HyClone, Logan, UT) and 100 units penicillin-streptomycin at 37 °C with 5% CO2 atmosphere in a humidified incubator.
One hundred and twenty-six archived paraffin-embedded PANC specimens were obtained from the Union Hospital, Tongji medical college, Huazhong university of science & technology from 2005 to 2010. Another nine PANC tissues and three adjacent non-tumour tissues frozen in liquid nitrogen were collected for further quantitative real-time reverse transcription PCR (qRT-PCR), western blotting, and immunohistochemical assays. No patients had received any anti-tumour treatments before biopsy. For the use of these human materials, prior consent and approval from the Institutional Research Ethics Committee of Huazhong University of Science and Technology were obtained, informed consent was obtained from the patients involved in the research, and all experiments were carried out in accordance with relevant guidelines and regulation. The clinical information for the patient samples is summarized in Table S1.
RNA extraction, reverse transcription, and qRT-PCR
Total RNA was extracted from freshly frozen samples or cells using the TRIzol reagent (Invitrogen). Total RNA was reverse-transcribed using a First Strand cDNA Synthesis Kit (Invitrogen). The real-time PCR reactions were conducted using Platinum SYBR Green qPCR SuperMix-UDG reagents (Invitrogen) on an Applied Biosystems 7500 Sequence Detection system. All reactions were done in triplicate and reactions without reverse transcriptase were used as negative controls. The human α-tubulin gene was used as the endogenous control and the 2−ΔΔCT equation was used to calculate the relative expression levels. The primers used to detect gene expression are shown in supplemental Table S3.
Matrix Metalloproteinase Activity Assays
MMP activity (MMP2 and MMP9) was measured by a fluorogenic peptide substrate (R&D Systems), according to the protocol recommended by the manufacturer. Briefly, the MMP substrate was diluted in TCN buffer (150 mmol/L NaCl, 10 mmol/L CaCl2, 50 mmol/L Tris-HCl; pH 7.5), and then was added to the supernatants (preactivated by aminophenylmercuric acetate for 1 hour) before incubation at 37 °C. After 30 minutes, total MMP activity was determined on a fluorometer (FLX 800 Microplate Fluorescence Reader; Bio-Tek Instruments, Winooski, VT).
Western blotting analysis
Total cell lysate was extracted using radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotechnology). Approximately 30 µg of protein was separated by 10% SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% skimmed milk, the membranes were incubated overnight with primary antibodies against CEP55 (Abcam, ab170414), MMP2 (Abcam, ab37150), MMP9 (Abcam, ab38898), Cyclin D1 (Abcam, ab134175), p-IKKβ (Abcam, ab59195), IKKβ (Abcam, ab32135) and IκBα (Abcam, ab32518), followed by incubation with secondary antibodies. Human α-tubulin (Abcam, ab7291) or GAPDH (Abcam, ab8245) were used as the endogenous references, according to the details. Immunoreactive protein bands were visualised using the ECL method (Invitrogen), according to the manufacturer’s recommendations.
Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded tissues. Antigen retrieval was performed by heating the slides at 95 °C in citrate buffer (pH 6.0) for 15 minutes before staining. The following primary antibodies were used: anti-CEP55 (Abcam, ab170414), anti-Cyclin D1 (Abcam, ab134175), and anti-MMP9 (Abcam, ab38898). Biotinylated Dolichos biflorus agglutinin (DBA) lectin (Vector Labs) was used at 1:250 in HEPES/NaCl. Staining of CEP55 was quantified using H-scores calculated from the staining intensity (0–3+) and percentage of stained cells (0–100%). The images were captured using the AxioVision Rel.4.6 computerized image analysis system (Zeiss).
Plasmids, retroviral infection, and transfection
The cDNAs of the human CEP55 or IκBα genes were amplified by PCR and cloned into the lentiviral vector pSin-EF2. Two human CEP55-targeting short hairpin RNA (shRNA) sequences (RNA#1: CCCAAGTGCAATATACAGTATCTCGAGATACTGTATATTGCAC TTG and RNA#2: GCAGCGGGAAGTCTATGTAAACTCGAGTTTACATAGACTTCCC GCT) were cloned into the pSuper-retro-puro vector to generate pSuper-retro-CEP55-RNAi(s). Retroviral production and infection were performed as described previously23. Stable cell lines that expressed CEP55 or CEP55-shRNAs were selected for 10 days using 0.5 mg/mL puromycin.
MTT assay and colony formation assay
PANC cells were seeded at 1500 cells per well in 96-well plates after transfection. The MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide) assay was performed to test cell viability at 1, 2, 3, 4, and 5 days, and the absorbance was measured at 490 nm using a spectrophotometric plate reader. For the colony formation assay, cells were plated at 500 cells per well in six-well plates after transfection, and cultured for 14 days. Colonies were fixed with methanol, stained with 0.5% crystal violet, and counted under an inverted microscope.
Transwell matrix penetration assay
Cells (1 × 104) were plated on the top side of a polycarbonate Transwell filter coated with Matrigel in the upper chamber of the BioCoat™ Invasion Chambers (BD, Bedford, MA, USA) and incubated at 37 °C for 22 h, followed by removal of cells inside the upper chamber with cotton swabs. Invaded cells on the lower membrane surface were fixed in 1% paraformaldehyde, stained with haematoxylin, and counted (10 random fields per well at 100× magnification).
Anchorage-independent growth assay
Five hundred cells were trypsinised and suspended in 2 ml completed medium plus 0.3% agar (Sigma). The agar-cell mixture was plated on top of a bottom layer with 1% agar completed medium mixture. After 10 days, viable colonies larger than 0.1 mm were counted. The experiment was carried out independently three times for each cell line.
Capan-1 cells stably expressing CEP55 or shCEP55 (3 × 106 cells/mouse) were injected subcutaneously into 4-week-old nude mice (Center for Experimental Animal of Guangzhou University of Chinese Medicine, Guangzhou, China). Stable CEP55-expressing Capan-1 cells and IκBα-lentivirus were co-injected subcutaneously into another group of nude mice. Tumour nodules were examined every three days, and were evaluated using the following formula: tumour volume = (Width2 × Length)/2. Mice were sacrificed 30 days after inoculation, and then the tumours were excised, weighed, and fixed for immunohistochemical staining. Animal protocols received the approval of the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology. All experiments were carried out in accordance with relevant guidelines and regulation.
Three thousand cells were seeded in 48-well plates and allowed to settle for 24 h. One hundred nanogrammes of luciferase reporter plasmids or the control luciferase plasmid plus 10 ng pRL-TK renilla plasmid (Promega) were transfected into PANC cells using the Lipofectamine 3000 reagent (Invitrogen). Luciferase and renilla signals were determined 24 h after transfection using a Dual Luciferase Reporter Assay Kit (Promega). Three independent experiments were performed and the data are presented as means ± standard deviation (SD).
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was performed using the LightShift Chemiluminescent EMSA Kit from Thermo Scientific, according to the manufacturer’s standard protocol. EMSA DNA probes were: NF-κB: sense, 5′-AGTTGAGGGGACTTTCCCAGGC-3′, antisense, 5′-GCCTGGGAAAGTCCCCTCAAC-3′; OCT-1: sense, 5′-TGTCGAATGCAAATCACTAGAA-3′, antisense, 5′-TTCTAGTGATTTGCATTCGACA-3′.
Microarray data processing and visualization
Microarray data were downloaded from The Cancer Genome Atlas (TCGA) database (http://cancergenome.nih.gov/). Analysis of CEP55 expression in PANC tissues compared with that in normal pancreas tissues was determined using a published microarray-based high-throughput assessment (n = 191, P < 0.001; NCBI/GEO/GSE71729). The data were downloaded from NCBI and analysed using SPSS 19.0 software. Gene Set Enrichment Analysis (GSEA) was performed using GSEA 2.0.9 (http://www.broadinstitute.org/gsea/).
Continuous variables are expressed as mean values ± SD, except where the SEM was used. The statistical tests for data analysis included Student’s two-tailed t-test, Chi-squared (χ2) tests, Fisher’s exact test, log-rank test, and Spearman correlation analysis. Univariate and multivariate statistical analysis were performed using a Cox regression model. Statistical analyses were performed using the SPSS 19.0 statistical software package; P < 0.05 was considered statistically significant.
Elevated CEP55 expression in PANC correlated with poor prognosis
To explore the expression of the CEP55 gene and its clinical significance in human PANC, first, we analysed CEP55 mRNA expression in primary pancreatic tumours from publicly available PANC datasets (TCGA and GSE71729). The GSEA plot indicated a significant correlation between the CEP55 mRNA expression level and those genes that were upregulated in PANC gene signatures (P < 0.001, Fig. S1a, GRUETZMANN_PANCREATIC_CANCER_UP; TCGA, n = 178, GSE71729, n = 145), which suggested an important role of CEP55 in PANC. Further analysis of the Gene Expression Omnibus (GEO) datasets showed that CEP55 mRNA was significantly elevated in patients with PANC compared with that in normal individuals (P < 0.001, Fig. 1a). In another publicly available PANC dataset (TCGA), CEP55 mRNA expression was higher in PANC patients with less than 5-year survival than in those with more than 5-year survival time (P < 0.01, Fig. 1b). Higher expression of CEP55 mRNA showed an inverse correlation with the 5-year survival of PANC patients (P < 0.05, Fig. 1c). Importantly, Kaplan-Meier analysis revealed that the expression levels of CEP55 mRNA in PANC specimens were inversely correlated with overall survival for patients with PANC (P < 0.05, Fig. 1d), which suggested that the CEP55 gene might serve as an indicator of poor survival in patients with PANC.
To validate the above analyses, we detected CEP55 mRNA and protein levels in normal pancreas cells (HPNE), PANC cell lines (Panc 03.27, Capan-1, Capan-2, SW1990, HPAF-II, Panc 10.05, BxPC-3, and CFPAC-1), and clinical specimens. Consistent with the published databases, Oncomine and TCGA, the levels of the CEP55 mRNA and CEP55 protein were significantly higher in PANC cell lines than in HPNE (Fig. 1e, left panel). Correlation analysis also revealed that CEP55 mRNA and protein levels correlated positively in the nine cell lines (Fig. 1e, right panel). In the clinical specimens, CEP55 mRNA and protein levels were elevated significantly in the nine PANC tissue samples compared with those in three adjacent non-tumour tissues (Fig. 2a and Fig. S1b).
To further evaluate relationship between CEP55 protein expression and the clinicopathological features of PANC, 126 archived paraffin-embedded PANC specimens were analysed by immunohistochemical staining using an antibody against human CEP55 (Fig. 2b, left panel). Quantitative immunohistochemical analysis revealed that the H-score of CEP55 staining was significantly increased in PANC specimens compared with that in adjacent non-tumour tissues (P < 0.05, Fig. 2b, right panel). Among these PANC specimens, 56 cases (44.4%) were identified as relatively low CEP55 expression, while 70 cases (55.6%) showed relatively high CEP55 expression (Table S1). Furthermore, up-regulated CEP55 protein was associated with TNM stage (P < 0.05) and clinical stage (P < 0.01), but no correlations were found with age or gender (Table S2). Importantly, Kaplan-Meier analysis revealed that the CEP55 protein expression levels in PANC specimens were inversely correlated with survival time (Fig. 2c). Finally, multivariate analysis was performed, which identified CEP55 expression as an independent prognostic factor of patient outcome (Fig. 2d). Taken together, our results indicated that CEP55 might represent a novel and potentially valuable independent biomarker for the prognosis of patients with PANC.
CEP55 overexpression promoted PANC cells aggressiveness
PANC is highly aggressive; therefore, we next investigated the effects of CEP55 on the proliferation, migration, and invasion of PANC cells. Initially, SW1990 and Capan-1 cell lines expressing CEP55 moderately were selected as cell models in this study according to the CEP55 expression in the PANC cell lines (Fig. 1e). CEP55 expression was detected by qRT-PCR and Western blot in SW1990 and Capan-1 cell lines upon transfected with CEP55 or CEP55 siRNA (Fig. 3a, Fig. S1c). Subsequently, MTT and colony formation assays were performed to evaluate the roles of CEP55 in PANC cell proliferation. The MTT assay revealed that CEP55 upregulation promoted SW1990 and Capan-1 cell proliferation (Fig. 3b). In the colony formation assay, CEP55 overexpression significantly increased the viability of SW1990 and Capan-1 cells, which formed more and larger colonies (P < 0.05, Fig. 3c). Conversely, silencing endogenous CEP55 in these cells markedly suppressed their proliferation and viability (Fig. 3b,c).
Next, wound-healing and Transwell matrix penetration assays were carried out to assess the effect of CEP55 on migration and invasion. As shown in Fig. 3d, CEP55 overexpression markedly accelerated SW1990 and Capan-1 cell migration compared with the vector control-transduced cells in the wound-healing assay, whereas silencing endogenous CEP55 in these cells reduced their migration capability (P < 0.05, Fig. 3d). In the Transwell matrix penetration assay, CEP55-overexpressing SW1990 and Capan-1 cells showed significantly increased invasion abilities, while CEP55 knockdown decreased it (P < 0.05, Fig. 3e). Take together, CEP55 overexpression promoted the proliferation, migration, and invasion of PANC cells in vitro, whereas downregulation of CEP55 expression attenuated it.
CEP55 upregulation accelerated PANC cells tumourigenicity
To further investigate the biological role of CEP55 in PANC cell aggressiveness, we evaluated the effect of CEP55 on the tumourigenicity in PANC cells. As shown in Fig. 4a, CEP55 overexpression markedly increased the anchorage-independent growth ability of SW1990 and Capan-1 cells in soft agar, as indicated by the increased colony number and size, whereas silencing endogenous CEP55 decreased tumourigenicity in these cells, which showed that CEP55 promoted PANC cells tumourigenicity in vitro.
The tumourigenicity capability of CEP55 was further examined using an in vivo murine model. SW1990/vector, SW1990/CEP55, Capan-1/scramble, or Capan-1/shCEP55 cells were injected subcutaneously into nude mice (n = 5 per group), and the growth morphologies of the implanted tumours were examined (Fig. 4b, left panel). The tumour growth rates were faster and their volumes were larger in CEP55-implanted mice than in the vector-implanted mice (Fig. 4b, right panel). Conversely, CEP55-silenced cells presented much slower tumour growth rates and formed smaller tumours (Fig. 4b). The tumour tissues were derived from these mice for further western blotting and immunohistochemical assays. Western blotting (Fig. 4c) and immunohistochemical assays (Fig. 4d) revealed the upregulation of invasion-related proteins MMP2 and MMP9, and proliferation-related protein Cyclin D1 in the CEP55-overexpressing tumour tissues, which coincided with the aggressive phenotype displayed by Capan-1/CEP55 cells. In contrast, MMP2, MMP9, and Cyclin D1 levels were decreased in tumour tissues with downregulated CEP55 expression (Fig. 4c,d). These results indicated that CEP55 accelerated PANC cells tumourigenicity and contributed to tumour progression in vivo.
The NF-κB pathway contributed to CEP55-mediated PANC aggressiveness and tumourigenicity
To identify the major pathways contributing to CEP55-mediated aggressiveness of PANC cells, we carried out correlation analysis between CEP55 expression and the possible signalling pathways in the GSEA database. CEP55 mRNA expression correlated positively with NF-κB-activated gene signatures (Fig. 5a), suggesting that CEP55 might activate the NF-κB signalling pathway. Indeed, ectopic expression of CEP55 increased significantly the NF-κB-driven luciferase reporter activity, whereas CEP55-knockdown decreased it (Fig. 5b). However, neither overexpression nor knockdown of CEP55 had any effect on the luciferase activities driven by mutated NF-κB (Fig. 5b), which further demonstrated that CEP55 plays an important role in modulation of NF-κB pathway. Furthermore, the expression of seven classically recognized NF-κB downstream targets, including MYC, CCND1, BCLXL, MMP9, TWIST, VEGFC, and IL6, were elevated on mRNA level in CEP55-overexpressing PANC cells (Fig. 5c). In contrast, CEP55 downregulation had the opposite effect (Fig. 5c). Further protein expression levels of C-Myc, Cyclin D1 and BCLXL were examined by western blotting assay. Consistently, we found that overexpression of CEP55 dramatically increased but silencing CEP55 decreased the expression of these NF-κB targets (Fig. 5d). These results suggested an important role of CEP55 in the activation of the NF-κB pathway.
IKKβ serves as a central intermediate signalling molecule in the activation of the NF-κB pathway; we assessed the effect of CEP55 modulation on IKKβ transcriptional activity in PANC cells. As expected, the expression levels of phosphorylated-IKKβ increased markedly in CEP55-transduced PANC cells, but decreased in CEP55-silenced cells (Fig. 5e). Consistently, levels of IκBα, the inhibitory protein of NF-κB, were reduced in CEP55-overexpressing PANC cells, whereas they were increased in CEP55-knockdown cells (Fig. 5e). Furthermore, EMSA revealed that NF-κB DNA-binding activity was increased drastically in CEP55-transduced cells and decreased in CEP55-silenced cells (Fig. 5f), suggesting that NF-κB signalling plays a critical role in promoting CEP55-mediated PANC aggressiveness.
To further validate that CEP55-mediated PANC cell aggressiveness acts via NF-κB activation, we blocked the NF-κB pathway by reintroducing the IκBα cDNA retrovirally or introducing the exogenetic NF-κB inhibitor JSH-23 into CEP55-overexpressing PANC cells. As expected, both IκBα and JSH-23 inhibited the stimulatory effect of CEP55 overexpression on NF-κB activation. MTT and colony formation assays showed that IκBα and JSH-23 suppressed the enhanced capabilities of proliferation and viability in PANC cells that were induced by CEP55 overexpression via NF-κB activation (Fig. 6a–c), whereas NF-κB pathway activation could partially rescue the reduced proliferation upon depletion of CEP55 (Fig. S2). Moreover, IκBα and JSH-23 also inhibited the elevated migratory and invasive capability in CEP55-overexpressing cells, as determined by wound-healing and Transwell matrix penetration assays (Fig. 6d,e). Importantly, the enhanced tumourigenicity was reversed by IκBα and the tumour volume was much smaller compared with that in CEP55-overexpressing Capan-1 cells (Fig. 6f). These results revealed that NF-κB pathway contributed to CEP55-mediated PANC aggressiveness and tumourigenicity in vitro and in vivo.
Finally, we examined whether CEP55 and NF-κB activation identified in PANC cells were clinically relevant. As shown in Fig. 7a and b, the PANC patients with relatively high CEP55 protein levels tended to have higher NF-κB DNA-binding activities and expressions of NF-κB target genes, including MYC, CCND1, BCLXL, MMP9, TWIST, VEGFC and IL6 (Fig. 7a,b and Fig. S3). Further correlation analysis revealed that CEP55 protein expression correlated positively with NF-κB activity (Fig. 7c), which further supported the notion that CEP55 could activate NF-κB pathway clinically. Taken together, these results suggested that CEP55 promoted PANC cells aggressiveness and tumourigenicity, probably by activating the NF-κB signalling pathway in patients with PANC.
The key finding of the present report is that CEP55 promotes PANC cell proliferation, migration/invasion, and tumourigenicity by activating the NF-κB signalling pathway. Elevated CEP55 expression in patients with PANC correlated with poor prognosis, whereas blocking the NF-κB pathway inhibited the CEP55-mediated aggressiveness of PANC cells, indicating that CEP55 represents a valuable prognostic indicator of outcome or is a potential therapeutic target for patients with PANC.
CEP55 is a key regulator of cytokinesis and promotes cell cycle transition15. It is located in the mitotic spindle during prometaphase and metaphase, and is recruited into the midbody during cytokinesis16, 24. Its aberrant expression has been proposed as an early event in tumourigenesis25. Increasing evidence shows that CEP55 has an oncogenic role and its overexpression correlates markedly with tumour stage, aggressiveness, and poor prognosis across multiple tumour types, such as gastric carcinoma, breast cancer, and ovarian carcinoma15, 20, 21, 26. In this study, CEP55 was detected as overexpressed in PANC cell lines and in patients with PANC. CEP55 promoted the proliferation, migration, and invasion in PANC cells in vitro. In an in vivo murine model, CEP55 overexpression accelerated PANC cells tumourigenicity, which was associated with upregulated levels of invasion-related proteins MMP2 and MMP9, and the proliferation-related protein Cyclin D1. CEP55 downregulation had the opposite effect. MMP2 and MMP9, as regulators of cell adhesion and invasion, are involved in augmenting the invasive capability of tumour cells, and correlate with the degree of histological malignancy and clinical outcome27, 28, while Cyclin D1 is associated with the proliferative ability of tumours. We believe that CEP55 accelerates PANC cell tumourigenicity in vivo by enhancing their proliferative and invasive capabilities, and functions as a novel oncogene in PANC aggressiveness.
NF-κB plays crucial roles in the regulation of inflammatory and immune responses, as well as in biological processes central to development of malignancies29. In about 70% pancreatic ductal adenocarcinoma, the NF-κB pathway is activated constitutively and is associated tightly with tumourigenesis, migration, and invasion9, 11, 12. By contrast, NF-κB signalling is key to immune function and is likely necessary for antitumor immunity30, 31. This presents a dilemma when designing therapeutic apprcoaches that target NF-κB. However, there is growing interest in identifying novel modulators to inhibit NF-κB activity, because impeding different steps of the NF-κB pathway has the potential to slow tumour growth, progression, and resistance to chemotherapy. In this study, the NF-κB pathway was hyperactivated in patients with PANC and contributed to CEP55-mediated proliferation, migration/invasion, and tumourigenicity in PANC cells in vitro and in vivo. Downregulated expression of CEP55 reduced, whereas CEP55 overexpression increased, the phosphorylation levels of IKKβ, an IκBα kinase, leading to IκBα degradation and release of NF-κB from the cytoplasm to the nucleus, where NF-κB activated the transcription of its downstream target, such as MYC, CCND1, BCLXL, MMP9, TWIST, VEGFC, and IL6. In patients with PANC, CEP55 protein expression and NF-κB activation were shown to be clinically relevant. Importantly, blocking the NF-κB pathway in PANC cells reversed CEP55-mediated PANC aggressiveness and tumourigenicity substantially. Taken together, these results revealed a novel molecular mechanism by which the NF-κB/IκBα pathway is hyperactivated in PANC and suggested that CEP55 or NF-κB/IκBα are potential targets for pharmacological intervention in PANC.
CEP55 was identified as a direct transcriptional target of forkhead box M1 (FOXM1)32. FOXM1 is overexpressed in PANC33 and its downregulation inhibits PANC cell growth, migration, and invasion, partly through the downregulation of NF-κB33. Another study revealed that CEP55 promotes FOXM1 expression34. Furthermore, both CEP55 and FOXM1 are regulated negatively by p53, a potent tumour suppressor35, 36, while mutations of p53 are frequently found in pancreatic ductal adenocarcinoma37. One hypothesis states that p53 inactivation or mutation leads to constitutive activation of a feedback loop between CEP55 and FOXM1, resulting in the enhanced aggressiveness in PANC via activation of the NF-κB pathway. However, further in-depth studies are needed to determine the precise molecular regulation of CEP55 and NF-κB, and their crosstalk, in cell growth, migration/invasion, and tumourigenicity in human PANC.
In summary, we demonstrated that CEP55 upregulation promotes PANC cell aggressiveness, such as cell proliferation, migration/invasion, and tumourigenicity. The aggressiveness-promoting role of CEP55 in PANC is associated with the degradation of IκBα and activation of NF-κB transactivity. Understanding the biological function of CEP55 in PANC will not only advance our knowledge of the mechanisms underlying CEP55 aggressiveness, but also will establish CEP55 and NF-κB/IκBα as significant prognostic factors or potential therapeutic targets to treat PANC.
Erkan, M. et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. GASTROENTEROLOGY 132, 1447–1464 (2007).
Razidlo, G. L. et al. Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. Cancer Res. 75, 2907–2915 (2015).
Bussom, S. & Saif, M. W. Methods and rationale for the early detection of pancreatic cancer. Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, FL, USA. January 22–24, 2010. JOP. 11, 128–130 (2010).
Shahrokni, A. & Saif, M. W. Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. JOP. 14, 391–394 (2013).
Bardou, M. & Le Ray, I. Treatment of pancreatic cancer: A narrative review of cost-effectiveness studies. Best Pract. Res. Clin. Gastroenterol 27, 881–892 (2013).
Goldstein, D. et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J. Natl. Cancer Inst. 107 (2015).
Wolfgang, C. L. et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 63, 318–348 (2013).
Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2, 301–310 (2002).
Maier, H. J. et al. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 295, 214–228 (2010).
Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D. & Fidler, I. J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20, 4188–4197 (2001).
Fujioka, S. et al. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 22, 1365–1370 (2003).
Wang, W. et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5, 119–127 (1999).
Gao, S. et al. IGFBP2 Activates the NF-kappaB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Cancer Res. 76, 6543–6554 (2016).
Tyagi, N. et al. p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-kappaB pathway. Oncotarget 5, 8778–8789 (2014).
Tao, J. et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol. 35, 4389–4399 (2014).
Fabbro, M. et al. Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev. Cell 9, 477–488 (2005).
Sakai, M. et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene 25, 480–486 (2006).
Chen, C. H. et al. FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene 26, 4272–4283 (2007).
Singh, P. K. et al. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma. Immunobiology 220, 103–108 (2015).
Wang, Y., Jin, T., Dai, X. & Xu, J. Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells. Biosci. Trends 10, 67–73 (2016).
Zhang, W. et al. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma. Tumour Biol. 37, 6239–6254 (2016).
Wang, G. et al. Centrosomal Protein of 55 Regulates Glucose Metabolism, Proliferation and Apoptosis of Glioma Cells via the Akt/mTOR Signaling Pathway. J. Cancer 7, 1431–1440 (2016).
Li, J. et al. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am. J. Pathol. 176, 699–709 (2010).
Zhao, W. M., Seki, A. & Fang, G. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol. Biol. Cell 17, 3881–3896 (2006).
Fournier, M. V. et al. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res. 66, 7095–7102 (2006).
Jeffery, J., Sinha, D., Srihari, S., Kalimutho, M. & Khanna, K. K. Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis. Oncogene 35, 683–90 (2016).
Deryugina, E. I. & Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25, 9–34 (2006).
Turpeenniemi-Hujanen, T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87, 287–297 (2005).
Baldwin, A. J. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649–683 (1996).
Sun, H., Lu, J., Liu, L., Yang, C. Y. & Wang, S. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. ACS Chem. Biol. 9, 994–1002 (2014).
Molinero, L. L. et al. NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J. Immunol. 173, 5583–5590 (2004).
Waseem, A., Ali, M., Odell, E. W., Fortune, F. & Teh, M. T. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol. 46, 536–542 (2010).
Wang, Z., Banerjee, S., Kong, D., Li, Y. & Sarkar, F. H. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 67, 8293–8300 (2007).
Chen, C. H. et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 28, 2723–2737 (2009).
Chang, Y. C., Wu, C. H., Yen, T. C. & Ouyang, P. Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1). J. Biol. Chem. 287, 4376–4385 (2012).
Pandit, B., Halasi, M. & Gartel, A. L. p53 negatively regulates expression of FoxM1. Cell Cycle 8, 3425–3427 (2009).
Chang, D. K., Grimmond, S. M. & Biankin, A. V. Pancreatic cancer genomics. Curr. Opin. Genet. Dev 24, 74–81 (2014).
This project was supported by grants from the National Natural Sciences Foundation of Hubei Province, China (No: 2015CFB621), the Fundamental Research Funds for the Union Hospital, Wuhan, China (No: 02.03.2015-57) and National Natural Science Foundation of China (No: 81302115; No: 81171840; No: 81670586).
The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Pathology - Research and Practice (2019)
Cell Cycle (2019)
Neuroscience Letters (2019)
MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55
Cancer Biology & Therapy (2018)
LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial–mesenchymal transition
Cancer Biology & Therapy (2018)